Citations

Clear

410 citation(s) found for "Shu, Yu".

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
Innocenti, Federico , Qu, Xueping , Niedzwiecki, Donna , Tam, Rachel, Mahajan, Shilpi, Goldberg, Richard M. , Blanke, Charles D. , Sanoff, Hanna K. , Atkins, James N., Polite, Blasé N. , Lenz, Heinz‐Josef , Kabbarah, Omar , Zemla, Tyler J, Niedzwiecki, Donna , Ou, Fang‐Shu , Zemla, Tyler , Bertagnolli, Monica M. , Venook, Alan P. , Sanoff, Hanna

Mayo Clinic

Journal of Clinical Oncology | March 13, 2019 | Volume: 37 | Issue: 14 | Pages: 1217-1227

10.1200/jco.18.01798 | PMID 30865548 Get It

PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant difference in overall survival (OS) in patients with first-line metastatic colorectal cancer treated with chemotherapy plus either bevacizumab or cetuximab. Primary tumor DNA from 843 patients has been used to discover genetic markers of OS. PATIENTS AND METHODS Gene mutations were determined by polymerase chain reaction. Microsatellite status was determined by genotyping of microsatellites. Tumor mutational burden (TMB) was determined by next-generation sequencing. Cox proportional hazard models were used, with adjusting factors. Interaction of molecular alterations with either the bevacizumab or the cetuximab arms was tested. RESULTS Patients with high TMB in their tumors had longer OS than did patients with low TMB (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.95]; P = .02). In patients with microsatellite instability–high (MSI-H) tumors, longer OS was observed in the bevacizumab arm than in the cetuximab arm (HR, 0.13 [95% CI, 0.06 to 0.30]; interaction P < .001 for interaction between microsatellite status and the two arms). Patients with BRAF mutant tumors had shorter OS than did patients with wild-type (WT) tumors (HR, 2.01 [95% CI, 1.49 to 2.71]; P < .001). Patients with extended RAS mutant tumors had shorter OS than did patients with WT tumors (HR, 1.52 [95% CI, 1.26 to 1.84]; P < .001). Patients with triple-negative tumors (WT for NRAS/ KRAS/ BRAF) had a median OS of 35.9 months (95% CI, 33.0 to 38.8 months) versus 22.2 months (95% CI, 19.6 to 24.4 months ) in patients with at least one mutated gene in their tumors ( P < .001). CONCLUSION In patients with metastatic colorectal cancer treated in first line, low TMB, and BRAF and RAS mutations are negative prognostic factors. Patients with MSI-H tumors benefited more from bevacizumab than from cetuximab, and studies to confirm this effect of MSI-H are warranted.
Randomized phase II trial of intravenous ascorbic acid (AA) as an adjunct to pazopanib for metastatic and unresectable clear cell renal cell carcinoma (ccRCC): A study of Academic and Community Cancer Research United (ACCRU) GU1703.
Cheville, John C. , Gartrell, Benjamin A. , Levine, Mark , Pagliaro, Lance C. , Shenoy, Niraj , Ou, Fang‐Shu , Bhagat, Tushar Damodar , Verma, Amit

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: TPS679-TPS679

10.1200/jco.2019.37.7_suppl.tps679 Get It

TPS679 Background: AA has re-emerged as a promising anti-cancer agent based on recent knowledge of pharmacokinetics, discovery of unexpected mechanisms of action, and early phase trials with IV AA.(Shenoy et al, Cancer Cell 34: 2018, in press) We hypothesized that ccRCC would be particularly susceptible to anti-cancer effects of IV AA due to: a. TET dependent demethylation of the hypermethylated genome of ccRCC causing re-expression of tumor suppressors (Shenoy et al, AACR 2018 Targeting DNA methylation conf. A11; Hu et al, Clin Cancer Res 20:4349-60, 2014) b. H2O2 production causing intra-tumoral oxidative damage, hypothesized to be enhanced by high iron content in RCC microenvironment c. Intracellular accumulation of dehydroascorbic acid secondary to high HIF activity in ccRCC. Animal data and case reports support the hypothesis. Methods: Trial design: Patients (pts) with newly diagnosed metastatic/ unresectable ccRCC are randomized 1:1 to arm A (pazopanib 800 mg/d plus IV AA 1g/kg 3 times/week) or arm B (pazopanib 800 mg/d). Protocol treatment is for 10 cycles (unless PD, unacceptable AE, alternative therapy, or pt refusal), each cycle being 28 days. Primary endpoint is Treatment Failure-Free rate at 40 weeks (TFF40). Treatment Failure is defined as: Radiographic disease progression, off-protocol treatment due to AE, alternative therapy initiation (except metastasectomy post clinical benefit), or death. Secondary endpoints include OS, PFS, ORR and AE. Statistical methods: 82 eligible pts (41 in each in arm) will provide 81% power to detect a 19% increase of TFF40 from 45% in arm B to 64% in arm A assuming a one-sided type I error rate of 0.19 (EAST 6.4). Correlatives: Epigenetic mechanism: 5mC, 5hmC and H3K27me3 IHC, MeDIP/ hMeDIP seq, RNA seq. H2O2 mechanism: tumor microenvironment iron, tumor catalase IHC. Dehydroascorbic acid mechanism: HIF-1 alpha, HIF-2 alpha, GLUT-1 IHC. Key exclusion criteria: G6PD deficiency, renal disease (Cockcroft Gault CrCl < 55 ml/min). ClinicalTrials.gov Identifier: NCT03334409 Status: Open for accrual in 9/10 planned sites. Funding Source: Foundation. Clinical trial information: NCT03334409.
Milestone prediction for time‐to‐event endpoint monitoring in clinical trials
Heller, Martin , Shi, Qian , Heller, Martin , Shi, Qian , Ou, Fang‐Shu

Mayo Clinic

Pharmaceutical Statistics | February 26, 2019 | Volume: 18 | Issue: 4 | Pages: 433-446

10.1002/pst.1934 | PMID 30806485 Get It

Predicting the times of milestone events, ie, interim and final analyses in clinical trials, helps resource planning. This manuscript presents and compares several easily implemented methods for predicting when a milestone event is achieved. We show that it is beneficial to combine the predictions from different models to craft a better predictor through prediction synthesis. Furthermore, a Bayesian approach provides a better measure of the uncertainty involved in prediction of milestone events. We compare the methods through two simulations where the model has been correctly specified and where the models are a mixture of three incorrectly specified model classes. We then apply the methods on two real clinical trial data, North Central Cancer Treatment Group (NCCTG) N0147 and N9841. In summary, the Bayesian prediction synthesis methods automatically perform well even when the data collection is far from homogeneous. AnRshiny app is under development to carry out the prediction in a user‐friendly fashion.
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
Hatch, Ace J. , Starr, Mark D. , Brady, John C. , Innocenti, Federico , Lenz, Heinz‐Josef , Hurwitz, Herbert I. , Ou, Fang‐Shu , Zemla, Tyler , Liu, Yingmiao , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Venook, Alan P. , Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 588-588

10.1200/jco.2019.37.4_suppl.588 Get It

588 Background: CALGB/SWOG 80405 found no difference in overall survival (OS) or progression-free survival (PFS) in 1137 patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with either the anti-VEGF agent bevacizumab (Bev) or the anti-EGFR agent cetuximab (Cet) in combination with chemotherapy (FOLFOX or FOLFIRI) as first-line therapy. Additional molecular biomarkers are required for the optimization of treatment choices for patients with mCRC. Methods: Levels of 24 proteins were assayed in EDTA-plasma samples using multiplex ELISA techniques. Plasma samples were collected at baseline and cycle 2 day 1 (C2D1). Analyses of baseline markers have been presented previously. Changes from baseline to C2D1 were expressed as an L-ratio (LR, log2 of C2D1 divided by baseline measure). LRs dichotomized at 0 were analyzed for potential prognostic and predictive effects on OS and PFS using Cox models while adjusting for confounders (post-hoc optimized cutpoints were used for PLGF, TIMP1, VCAM1, and VEGFR3 due to skew in the distributions of these markers). P-values are not corrected for multiple testing. Results: Baseline and matched C2D1 samples from 446 patients (212 Bev/234 Cet) were available for analysis. Thirteen markers were differentially modulated between arms (p < 0.05). Early increases in CD73 (p = 0.001), ICAM1 (p = 0.022), TIMP1 (p = 0.001), TSP2 (p = 0.024), and VEGFR3 (p = 0.006) were prognostic for shorter OS. Increases in ICAM1 (p = 0.008), TIMP1 (p = 0.042), and TGFB1 (p = 0.039) were prognostic for shorter PFS. Changes in VEGFR3 (pint = 0.097) and TGFBR3 (pint = 0.052) were predictive for OS and PFS, respectively. No other markers were predictive for OS or PFS (p < 0.1). Conclusions: Changes in circulating plasma protein biomarkers observed in patients enrolled in CALGB/SWOG 80405 were both prognostic and predictive for OS and PFS and warrant further study. Such changes could provide valuable information and help guide treatment decisions. Support: U10CA180821, U10CA180882, U10CA180888, U10CA180830; ClinicalTrials.gov: NCT00265850. [Table: see text]
Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)
Song, Mingyang , Hull, Mark A. , Shi, Qian , Giovannucci, Edward L. , Blarigan, Erin L. Van , Meyerhardt, Jeffrey A. , Zemla, Tyler J, Limburg, Paul J. , Meyerhardt, Jeffrey A , Shi, Qian , Song, Mingyang , Ou, Fang‐Shu , Zemla, Tyler , Alberts, Steven R. , Sinicrope, Frank A. , Chan, Andrew T.

Mayo Clinic

International Journal of Cancer | January 9, 2019 | Volume: 145 | Issue: 2 | Pages: 380-389

10.1002/ijc.32113 | PMID 30623420 Get It

Marine omega‐3 polyunsaturated fatty acids (MO3PUFAs) have anticancer properties and may improve colon cancer survival. However, it remains unknown whether the benefit differs by tumor molecular subtype. We examined data from a phase III randomized trial of FOLFOX or FOLFOX + cetuximab among 1,735 stage III colon cancer patients who completed a dietary questionnaire at enrollment. Multivariable hazard ratios and 95% confidence intervals (CIs) were calculated for the association between MO3PUFA and disease‐free survival (DFS) and overall survival according toKRASandBRAFV600Emutations and DNA mismatch repair (MMR) status. Higher MO3PUFA intake was associated with improved 3‐year DFS forKRASwild‐type tumors (77%vs. 73%; HR: 0.84; 95% CI: 0.67–1.05) but notKRAS‐mutant tumors (64%vs. 70%; HR: 1.30; 95% CI: 0.97–1.73;Pinteraction= 0.02). Similar heterogeneity was found by MMR (Pinteraction= 0.14): higher MO3PUFA was associated with better 3‐year DFS for tumors with deficient MMR (72%vs. 67%) but not proficient MMR (72%vs. 72%). No heterogeneity was found byBRAFV600Emutation. Similar findings were obtained for overall survival. In conclusion, we found a suggestive beneficial association between higher MO3PUFA intake and improved survival among stage III colon cancer patients with wild‐typeKRASand deficient MMR. Given the relatively small number of cases with tumor molecular assessments, further studies, preferably through pooled analyses of multiples cohorts, are needed to validate our findings.
Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database.
Lou, Yiyue , Goldberg, Richard M. , Douillard, Jean‐Yves , Hecht, J. Randolph , Hurwitz, Herbert I. , Punt, Cornelis J.A. , Bokemeyer, Carsten , Fuchs, Charles S. , Tebbut, Niall, Kabbinavar, Fairooz F. , Gramont, Aimery de , Ou, Fang‐Shu , Cutsem, Eric Van , Saltz, Leonard B. , Schmoll, Hans‐Joachim , Hoff, Paulo M. , Díaz‐Rubio, Eduardo , Falcone, Alfredo , Grothey, Axel , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 612-612

10.1200/jco.2018.36.4_suppl.612 Get It

612 Background: mCRC is a heterogeneous disease leading to possible disparate responses among lesions in a single pt. This study assesses the heterogeneity of lesion responses and evaluates the prognostic value of LBR12 and its mortality risk discrimination beyond RECIST responses. Methods: Pts with ≥ 2 lesions and no new lesions at 12 weeks (wks) were eligible. For each pt, after 12 wks of Rx, each lesion was categorized as progressive disease (L-PD: ≥20% increase in the longest diameter [LD]), partial response (L-PR: ≥30% decrease in LD), or stable disease (L-SD: neither L-PD nor L-PR). LBR12 was defined, per patient, by the combination of lesion responses: homogeneous LBR12 (L-PD, L-SD, L-PR only) and heterogeneous LBR12 (mixture of L-PD/L-SD, L-PD/L-PR, L-SD/L-PR). LBR12 and overall survival (OS) were correlated using stratified multivariate Cox models after adjusting for age, gender, and ECOG PS. Results: Among 9,092 mCRCs (Rx: chemo alone 44%; chemo + VEGF inhibitor [VEGFi] 42%; chemo + EGFR inhibitor [EGFRi] 10%) from 16 1st-line studies. Median OS: 2.2 years. Per RECIST at 12 wks, CR 0%; PR 36.1%; SD 60.9%; PD 3.0%. Responses in 52% were heterogeneous (Table). VEGFi and EGFRi treated pts had the highest rate of L-SD/L-PR (45%) and L-PR only (22%) status, respectively. Median OS increased monotonically across pts with more L-PRs and fewer L-PDs (Table). Pts with L-SD/L-PR status, among which 51% had SD per RECIST, had longer OS than those with L-SD only status (HRadj.= .81, padj.< .0001), but shorter OS than those with L-PR only status (HRadj.= 1.46, padj.< .0001). Pts with L-PD/L-SD status, among which 71% were SD per RECIST, had shorter OS than those with L-SD only status (HRadj.= 2.22, padj.< .0001). These associations were consistent across treatment regimens. Conclusions: The lesion-based response captures the heterogeneity of within pt lesion responses and provides refinement in predicting outcome beyond RECIST response at 12 wks. [Table: see text]
Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)–An ACCRU Network study.
Anderson, Daniel M. , Ahn, Daniel H. , Ciombor, Kristen K. , Jacobs, Nisha L. , Desnoyers, Rodwige J., Cleary, James M. , Meyers, Jeffrey P., Chiorean, E. Gabriela , Sloan, Jeffrey A., McCune, Jeannine S. , Lenz, Heinz Josef, Bekaii‐Saab, Tanios , Ou, Fang‐Shu , Boland, Patrick M. , Pedersen, Katrina S. , Barzi, Afsaneh , Lacouture, Mario E. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 611-611

10.1200/jco.2018.36.4_suppl.611 Get It

611 Background: Regorafenib is an oral multikinase inhibitor with survival benefit in refractory mCRC patients (pts). Toxicities such as Palmar-plantar erythrodysesthesia syndrome (PPES), fatigue and hypertension (HTN) have limited its use. Despite absence of supportive data, various dosing or interval scheduling have been implemented into clinical practice. Methods: A randomized phase II study of regorafenib dose-escalation (Arm A: 80 mg/day, weekly dose escalation if no significant drug-related toxicities, up to 160 mg/day) vs. standard dose (Arm B: 160 mg/day) in pts with mCRC for 21 days of a 28-day cycle. Pts were randomized 1:1:1:1 to arms A1 and B1 (Pre-emptive Clobetasol for PPES); A2 and B2 (Reactive Clobetasol). The primary endpoint was the proportion of patients who completed 2 cycles of treatment and initiated the 3rd in Arm A (Pooled A1 + A2) vs. Arm B (Pooled B1 + B2). Superiority for Arm A was to be declared if the one-sided p-value calculated using Fisher’s exact method was less than 0.2. Results: From June 2015 to June 2017, 123 pts were randomized with 116 (A = 54, B = 62) evaluable for the primary endpoint. Demographic data were well balanced with overall median age of 61yrs (range: 29-81), M/F (61/39%) and ECOG PS 0/1 (37/63%) and KRAS MT/WT/UNK (47/44/9%).The study met its primary endpoint with 43% of pts on Arm A initiating the 3rd vs. only 25% of pts Arm B [one-sided p-value 0.028]. Median Overall Survival (OS) was improved in Arm A vs. Arm B (9.0 mos vs. 5.9 mos; p = 0.094). Median Progression Free Survival (PFS) was 2.5 mos for Arm A vs. 2.0 mos for Arm B (p=0.553). Overall rates of grade 3/4 toxicity were more favorable for Arm A vs. Arm B (% PPES 15 vs. 16, HTN 7 vs. 15 and fatigue 13 vs. 18, respectively). Multiple QOL parameters were improved in A vs. B primarily at week 2 of the first cycle. Conclusion: A strategy with weekly dose escalation of regorafenib from 80 mg to 160 mg/day was found to be superior to a starting dose of 160 mg/day. These results establish a new standard for optimizing regorafenib dosing. Further data on outcomes of preemptive vs. reactive clobetasol strategies are undergoing analysis and will be presented later. Clinical trial information: NCT02368886.
Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk
Yang, Yaohua , Wu, Lang , Shu, Xiao-Ou , Lu, Yingchang , Beeghly‐Fadiel, Alicia, Li, Bingshan , Ye, Fei , Banerjee, Susana , Benı́tez, Javier , Chang‐Claude, Jenny , Chen, Kexin , DeFazio, Anna , Dörk, Thilo , Eccles, Diana M., Edwards, Digna Velez, Fasching, Peter A. , Fortner, Renée T. , Gayther, Simon A. , Goode, Ellen L. , Goodman, Marc T. , Heitz, Florian , Hildebrandt, Michelle A.T., Høgdall, Estrid , Høgdall, Claus , Huntsman, David G. , Kar, Siddhartha , Kelemen, Linda E. , Koushik, Anita , Lambrechts, Diether , Le, Nhu D. , Levine, Douglas A. , Massuger, Leon F.A.G. , Matsuo, Keitaro , May, Taymaa, McNeish, Iain A. , Menon, Usha , Monteiro, Álvaro N.A. , Moorman, Patricia G. , Moysich, Kirsten B. , Ness, Roberta B., Olsson, Håkan , Onland‐Moret, N. Charlotte , Park, Sue K. , Paul, James , Pearce, Celeste Leigh, Phelan, Catherine M., Pike, Malcolm C. , Ramus, Susan J. , Ríboli, Elio , Rodríguez‐Antona, Cristina , Romieu, Isabelle, Sandler, Dale P. , Schildkraut, Joellen M. , Shan, Kang, Sieh, Weiva , Stampfer, Meir J. , Sutphen, Rebecca , Swerdlow, Anthony J. , Szafron, Lukasz M. , Teo, Soo‐Hwang , Tworoger, Shelley S. , Webb, Penelope M. , Wentzensen, Nicolas , Woo, Yin Ling , Wu, Anna H. , Chenevix‐Trench, Georgia , Sellers, Thomas A. , Long, Jirong , Eccles, Diana , Lambrechts, Diether , Chen, Kexin , Shu, Xiao-Ou , Brenton, James D , Chang-Claude, Jenny , Fazio, Anna de , Dennis, Joe , Fasching, Peter A , Fortner, Renée T , Giles, Graham G , Harris, Holly R , Kiemeney, Lambertus A , Kjaer, Susanne K , Koushik, Anita , McNeish, Iain A , Menon, Usha , Monteiro, Alvaro N , Nevanlinna, H , Park, Sue K , Paul, James , Ramus, Susan J , Rodríguez-Antona, Cristina , Sandler, Dale P , Szafron, Lukasz M , Teo, Soo H , Tworoger, Shelley S , Webb, Penelope M , Wolk, Alicja , Dörk, Thilo , Lambrechts, Diether , Eccles, Diana , Swerdlow, Anthony J , Moysich, Kirsten , Matsuo, Keitaro , Heitz, Florian , Lambrechts, Diether , Sieh, Weiva , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Riboli, Elio , Goodman, Marc T , Cai, Qiuyin , Beeghly‐Fadiel, Alicia , Berchuck, Andrew , Anton‐Culver, Hoda , Bjørge, Line , Brenton, James D. , Bützow, Ralf C. , Campbell, Ian , Cook, Linda S. , Cramer, Daniel W. , Doherty, Jennifer A. , Edwards, Digna R. Velez , Giles, Graham G. , Glasspool, Rosalind , Gronwald, Jacek , Harris, Holly R. , Hildebrandt, Michelle A.T. , Karlan, Beth Y. , Kiemeney, Lambertus A. , Kjær, Susanne K. , Modugno, Francesmary , Nevanlinna, Heli , Pejovic, Tanja B. , Setiawan, Veronica Wendy , Shan, Kang, Siddiqui, Nadeem , Tyrer, Jonathan P. , White, Emily , Willett, Walter C. , Wolk, Alicja , Li, Yan , Yannoukakos, Drakoulis , Pharoah, Paul D.P. , Zheng, Wei , Yang, Yaohua , Chen, Kexin

Mayo Clinic

Cancer Research | December 17, 2018 | Volume: 79 | Issue: 3 | Pages: 505-517

10.1158/0008-5472.can-18-2726 | PMID 30559148 Get It

Abstract DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study (N = 1,595) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of P &lt; 7.94 × 10−7. Of them, 87 were located at GWAS-identified EOC susceptibility regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27, and SKAP1. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression. Significance: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression.
Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer
Gerke, Travis , Beltran, Himisha , Lee, Gwo‐Shu Mary , Karnes, R. Jeffrey , Klein, Eric A. , Davicioni, Elai , Yousefi, Kasra, Ross, Ashley E. , Börnigen, Daniela , Mucci, Lorelei A. , Sweeney, Christopher J. , Davicioni, Elai , Klein, Eric A , Sweeney, Christopher , Wang, Xiaodong , Sboner, Andrea , Huttenhower, Curtis , Trock, Bruce J

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 12, 2018 | Volume: 28 | Issue: 3 | Pages: 584-590

10.1158/1055-9965.epi-18-0667 | PMID 30420441 Get It

Abstract Background: Inflammation is linked to prostate cancer progression and is mediated by NF-κB. Tristetraprolin is a key node of NF-κB activation and we investigated its biological and prognostic role in lethal prostate cancer. Methods: In vitro assays assessed the function of tristetraprolin and the association between low mRNA tristetraprolin levels and lethal prostate cancer (metastatic disease or death) was assessed across independent prostatectomy cohorts: (i) nested case-control studies from Health Professionals Follow-up Study and Physicians’ Health Study, and (ii) prostatectomy samples from Cleveland Clinic, Mayo Clinic, Johns Hopkins and Memorial Sloan Kettering Cancer Center. Tristetraprolin expression levels in prostatectomy samples from patients with localized disease and biopsies of metastatic castration–resistant prostate cancer (mCRPC) were assessed in a Cornell University cohort. Results: In vitro tristetraprolin expression was inversely associated with NF-κB–controlled genes, proliferation, and enzalutamide sensitivity. Men with localized prostate cancer and lower quartile of tumor tristetraprolin expression had a significant, nearly two-fold higher risk of lethal prostate cancer after adjusting for known clinical and histologic prognostic features (age, RP Gleason score, T-stage). Tristetraprolin expression was also significantly lower in mCRPC compared with localized prostate cancer. Conclusions: Lower levels of tristetraprolin in human prostate cancer prostatectomy tissue are associated with more aggressive prostate cancer and may serve as an actionable prognostic and predictive biomarker. Impact: There is a clear need for improved biomarkers to identify patients with localized prostate cancer in need of treatment intensification, such as adjuvant testosterone suppression, or treatment de-intensification, such as active surveillance. Tristetraprolin levels may serve as informative biomarkers in localized prostate cancer.
Improving apparent diffusion coefficient accuracy on a compact 3T MRI scanner using gradient nonlinearity correction
Tao, Ashley , Shu, Yunhong , Trzasko, Joshua D. , Tao, Shengzhen , Reid, Robert D., Weavers, Paul T., Tao, Ashley T , Tao, Shengzhen , Tan, Ek T. , Huston, John , Bernstein, Matt A.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 26, 2018 | Volume: 48 | Issue: 6 | Pages: 1498-1507

10.1002/jmri.26201 | PMID 30255963 Get It

BackgroundGradient nonlinearity (GNL) leads to biased apparent diffusion coefficients (ADCs) in diffusion‐weighted imaging. A gradient nonlinearity correction (GNLC) method has been developed for whole body systems, but is yet to be tested for the new compact 3T (C3T) scanner, which exhibits more complex GNL due to its asymmetrical design.PurposeTo assess the improvement of ADC quantification with GNLC for the C3T scanner.Study TypePhantom measurements and retrospective analysis of patient data.Phantom/SubjectsA diffusion quality control phantom with vials containing 0–30% polyvinylpyrrolidone in water was used. For in vivo data, 12 patient exams were analyzed (median age, 33).Field Strength/SequenceImaging was performed on the C3T and two commercial 3T scanners. A clinical DWI (repetition time [TR] = 10,000 msec, echo time [TE] = minimum, b = 1000 s/mm2) sequence was used for phantom imaging and 10 patient cases and a clinical DTI (TR = 6000–10,000 msec, TE = minimum, b = 1000 s/mm2) sequence was used for two patient cases.AssessmentThe 0% vial was measured along three orthogonal axes, and at two different temperatures. The ADC for each concentration was compared between the C3T and two whole‐body scanners. Cerebrospinal fluid and white matter ADCs were quantified for each patient and compared to values in literature.Statistical TestsPaired t‐test and two‐way analysis of variance (ANOVA).ResultsFor all PVP concentrations, the corrected ADC was within 2.5% of the reference ADC. On average, the ADC of cerebrospinal fluid and white matter post‐GNLC were within 1% and 6%, respectively, of values reported in the literature and were significantly different from the uncorrected data (P < 0.05).Data ConclusionThis study demonstrated that GNL effects were more severe for the C3T due to the asymmetric gradient design, but our implementation of a GNLC compensated for these effects, resulting in ADC values that are in good agreement with values from the literature.Level of Evidence: 4Technical Efficacy: Stage 2J. Magn. Reson. Imaging 2018;48:1498–1507